The short answer: No money was taken from Medicare itself, but the law did redirect some future Medicare savings to fund other programs.
In 2022, President Biden signed the Inflation Reduction Act into law. That law included a provision that changed how Medicare negotiates drug prices. When Medicare negotiates lower drug prices, the government saves money. Under this law, some of those savings — not money already in Medicare — were directed toward funding climate and energy programs instead of staying in the Medicare trust fund.
This is different from "taking money out" of Medicare in the way many people imagine it. Medicare's current operations and benefits were not cut. But the law did mean that future savings from drug price negotiations would be split: some stays in Medicare, and some goes elsewhere. That split is what sparked the debate.
Key Takeaways
- The Inflation Reduction Act redirected some future Medicare savings from drug price negotiations to other federal programs, but did not reduce current Medicare benefits or payments to providers.
- Medicare's Hospital Insurance Trust Fund (Part A) receives its money from payroll taxes, and that funding stream was not changed by the law.
- The amount redirected varies by year and depends on how much Medicare actually saves through drug price negotiations, which is not fixed in advance.
- Your Medicare coverage, copays, and deductibles were not affected by this change, though future drug prices negotiated by Medicare may be lower.
How the Inflation Reduction Act changed Medicare drug savings
Before 2022, when Medicare negotiated lower drug prices, all of the savings went back into the Medicare trust fund. The Inflation Reduction Act changed that split. Now, when Medicare negotiates a lower price for a covered drug, the savings are divided: some portion stays in Medicare, and the rest goes to deficit reduction (which funds other government programs).
The exact amount redirected depends on how much Medicare actually saves each year. Because drug prices and negotiation outcomes vary, the dollar amount is not fixed. The law does not specify a flat sum — it is a percentage of whatever savings occur.
This matters because it means the impact on Medicare's finances grows or shrinks depending on real-world drug price negotiations. If Medicare negotiates very large price cuts, more money is redirected. If negotiations result in smaller savings, less is redirected.
What this means for your current Medicare benefits
Your current benefits — what you can see, what you pay, what Medicare covers — did not change because of this law. If you are already on Medicare, your Part A (hospital insurance), Part B (medical insurance), Part D (prescription drug coverage), and any supplemental or advantage plan work the same way they did before.
Your copays and deductibles were not affected. Your provider payments were not cut. The change only affects how future savings from drug price negotiations are distributed, not how Medicare operates today.
Over time, if Medicare successfully negotiates lower drug prices, you may see lower out-of-pocket costs for those drugs. That is a direct benefit to you. The redirection of savings does not prevent those price negotiations from happening — it just means the government does not keep all of the savings in the Medicare trust fund.
The difference between current spending and future savings
A key point of confusion: the law did not take money that was already in Medicare and spend it elsewhere. It redirected future savings — money that would have been added to Medicare's reserves in years to come.
Medicare's Hospital Insurance Trust Fund (Part A) is funded by payroll taxes paid by workers and employers. That tax rate and that funding stream were not changed. The trust fund continues to receive those taxes. The question was only what to do with the extra money that Medicare saves when it negotiates drug prices down.
Think of it this way: if you negotiate a lower price on your car insurance and save $200 a year, that $200 is new money you did not have before. The law says Medicare must give some of that new money to other programs instead of keeping all of it. It does not mean your insurance company took money out of your existing account.
Why this became controversial
Critics of the law argued that redirecting Medicare savings weakens the trust fund's long-term finances. They said that money should stay in Medicare to help pay for future benefits as the population ages.
Supporters argued that the law still allows Medicare to negotiate drug prices (which it could not do before for most drugs), and that the savings — even after redirection — are a net gain for both Medicare and the federal budget.
Both sides agree on the facts of what the law does. They disagree on whether it is the right policy choice. That is a question about values and priorities, not about what actually happened to your benefits.
What the law actually allows Medicare to do
The Inflation Reduction Act gave Medicare the power to negotiate drug prices directly with pharmaceutical companies for the first time. Before this law, Medicare could not negotiate — it had to pay whatever price manufacturers set.
Starting in 2026, Medicare can negotiate prices for a small number of high-cost drugs. The number of drugs Medicare can negotiate grows over time. This is separate from the question of where the savings go — it is about whether Medicare can negotiate at all.
Many people on Medicare may see lower drug costs as a result, because negotiated prices are typically lower than list prices. Whether those savings stay entirely in the Medicare trust fund or are partially redirected does not change the fact that the drugs cost less.
How this affects Medicare's long-term solvency
The Medicare Hospital Insurance Trust Fund (Part A) has a projected date when it will run out of money if no changes are made — this date is called the trust fund depletion date. Redirecting drug savings does push that date closer, meaning the trust fund would run out sooner than it would have if all savings stayed in Medicare.
However, the trust fund's main challenge is not drug savings — it is the aging population and rising healthcare costs overall. The trust fund faces long-term pressure from many sources, and the redirection of drug savings is one factor among many.
Congress would need to take additional steps to may support the trust fund remains solvent long-term, such as adjusting payroll taxes, changing benefit structures, or finding other revenue sources. The Inflation Reduction Act addressed drug price negotiation and climate funding, but did not solve the broader solvency question.
Frequently Asked Questions
Did my Medicare benefits get cut because of this law?
No. Your current benefits, coverage, copays, and deductibles were not changed. The law only affects how future savings from drug price negotiations are distributed, not how Medicare operates or what it covers today.
Will my drug costs go down because of this?
Possibly. Starting in 2026, Medicare can negotiate prices for certain high-cost drugs, which may result in lower prices for those medications. Whether you benefit depends on which drugs you take and whether Medicare negotiates prices for them.
Does this mean Medicare will run out of money sooner?
The redirection of drug savings does move up the projected trust fund depletion date somewhat. However, the trust fund's main challenge is the aging population and rising healthcare costs. Long-term solvency requires broader policy changes beyond this one law.
Can Medicare still negotiate drug prices even though some savings are redirected?
Yes. The law gives Medicare the power to negotiate drug prices for the first time. The fact that some savings go to other programs does not prevent Medicare from negotiating or from passing lower prices on to beneficiaries.
Where exactly does the redirected money go?
The redirected savings go toward deficit reduction, which means they are used to fund other federal programs and reduce the overall federal budget deficit. The law does not specify a single program — it is a general budget mechanism.